Fig. 1
From: Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
PET-CT for a patient with metastatic melanoma and baseline cirrhosis of the liver (a) and near complete response four months after initiating treatment (b)